The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact

• Jonathan J. Pinney,
• Sara K. Blick-Nitko,
• Andrea M. Baran,
• Derick R. Peterson,
• Hannah E. Whitehead,
• Raquel Izumi,
• Veerendra Munugalavadla,
• Karl R. Van DerMeid,
• Paul M. Barr,
• Clive S. Zent,
• Michael R. Elliott,
• Charles C. Chu

Affiliations

Jonathan J. Pinney

Center for Vaccine Biology and Immunology; Department of Microbiology and Immunology, University of Rochester, Rochester, NY

Sara K. Blick-Nitko

Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY

Andrea M. Baran

Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY

Derick R. Peterson

Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY

Hannah E. Whitehead

Center for Vaccine Biology and Immunology; Department of Microbiology and Immunology, University of Rochester, Rochester, NY

Raquel Izumi

Acerta Pharma, a member of the AstraZeneca Group, South San Francisco, CA

Veerendra Munugalavadla

AstraZeneca, South San Francisco, CA

Karl R. Van DerMeid

Department of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

Paul M. Barr

Department of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

Clive S. Zent

Department of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

Michael R. Elliott

Center for Vaccine Biology and Immunology; Department of Microbiology and Immunology, University of Rochester, Rochester, NY, USA; Center for Cell Clearance and the Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, VA

Charles C. Chu

Department of Medicine; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY